Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PETS
PETS logo

PETS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.330
Open
2.320
VWAP
2.26
Vol
106.28K
Mkt Cap
47.72M
Low
2.210
Amount
239.85K
EV/EBITDA(TTM)
--
Total Shares
21.40M
EV
20.82M
EV/OCF(TTM)
--
P/S(TTM)
0.25
PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Show More

Events Timeline

(ET)
2026-01-09
08:50:00
BTQ Technologies Corp. Borrow Rate Increases to 18.41%
select
2025-12-16 (ET)
2025-12-16
12:10:00
Cardone Ventures Proposes to Acquire PetMed Express for $4.25 per Share
select
2025-12-11 (ET)
2025-12-11
09:50:00
PetMed Express Receives $4 Acquisition Proposal from SilverCape
select
2025-12-10 (ET)
2025-12-10
08:10:00
PetMeds Unveils New Holiday Collection
select
2025-11-13 (ET)
2025-11-13
08:08:22
PetMed Express announces estimated Q2 revenue between $43.4M and $44.5M
select
2025-10-20 (ET)
2025-10-20
08:41:51
James LaCamp Joins PetMed Express Board of Directors
select
2025-08-12 (ET)
2025-08-12
16:50:50
PetMed Express CEO Sandra Campos, CFO Robyn D'Elia resign
select
2025-07-03 (ET)
2025-07-03
08:36:43
PetMed Express receives non-compliance notice from Nasdaq
select
2025-07-01 (ET)
2025-07-01
08:37:34
PetMed Express says unable to file 2025 Form 10-K within extension period
select

News

PRnewswire
7.0
01-08PRnewswire
PetMed Express Faces Investigation Over Delayed Earnings, Stock Plummets 32.41%
  • Financial Audit Delay: PetMed Express announced on June 10, 2025, a delay in releasing its Q4 and fiscal year 2025 earnings, causing a stock drop of 11.22% the following day, reflecting investor concerns over the company's financial transparency.
  • Impact of Internal Investigation: On July 1, 2025, PetMed delayed its annual report due to an internal investigation into revenue recognition, leading to a 1.51% decline in stock price, indicating that governance and compliance issues may undermine investor confidence.
  • Quarterly Report Delay: On November 12, 2025, PetMed disclosed it could not timely file its Q3 report, resulting in a 32.41% plunge in stock price to $1.96, highlighting a significant crisis in financial management that could lead to broader legal and financial repercussions.
  • Legal Investigation Initiated: Pomerantz LLP is investigating whether PetMed engaged in securities fraud or other unlawful business practices, suggesting the company faces potential legal liabilities that could further impact its market performance and shareholder interests.
PRnewswire
7.0
01-01PRnewswire
PetMed Express Faces Investigation Over Delayed Earnings, Stock Plummets 32.41%
  • Audit Delay: On June 10, 2025, PetMed Express announced a delay in releasing its Q4 and fiscal year 2025 earnings, causing its stock to drop 11.22% the following day, reflecting market concerns over the company's financial transparency.
  • Internal Investigation Impact: On July 1, 2025, PetMed delayed its annual report due to an internal investigation into revenue recognition, leading to a 1.51% decline in stock price, indicating a weakening investor confidence in corporate governance.
  • Quarterly Report Delay: On November 12, 2025, PetMed disclosed it could not timely file its Q3 report, resulting in a 32.41% stock plunge to $1.96, highlighting severe financial compliance issues that may affect future financing capabilities.
  • Legal Investigation Initiated: Pomerantz LLP is investigating whether PetMed engaged in securities fraud or other unlawful business practices, which could lead to further legal liabilities and financial losses, increasing uncertainty for investors.
Globenewswire
7.0
2025-12-30Globenewswire
PetMed Express Faces Investigation Over Delayed Earnings, Stock Plummets 32.41%
  • Earnings Delay Impact: On June 10, 2025, PetMed Express announced a delay in releasing its Q4 and FY 2025 earnings, causing its stock to drop 11.22% to $3.72 per share the following day, indicating investor concerns over the company's financial transparency.
  • Internal Investigation Effects: On July 1, 2025, PetMed revealed a delay in filing its Annual Report due to an internal investigation, leading to a further 1.51% decline in stock price to $3.27 per share, reflecting diminished market confidence in the company's revenue recognition practices.
  • Quarterly Report Delay: On November 12, 2025, PetMed disclosed its inability to timely file its Q3 report, resulting in a dramatic 32.41% drop in stock price to $1.96 per share, highlighting serious issues in corporate governance and audit processes that could affect future financing capabilities.
  • Legal Investigation Initiated: Pomerantz LLP is investigating whether PetMed engaged in securities fraud or other unlawful business practices, which could lead to further legal risks and financial losses, increasing uncertainty for investors.
Benzinga
7.5
2025-12-25Benzinga
U.S. Pet Spending Resilience in 2025 Highlights Shift in Consumer Behavior
  • Resilience in Pet Spending: In 2025, U.S. pet spending demonstrated resilience despite ongoing cost-of-living pressures, with pet and pet product inflation easing to 0.3% in November, providing relief to consumers and highlighting the sector's defensive appeal.
  • Shift in Consumer Behavior: A survey revealed that 97% of U.S. pet owners consider their pets family members, driving demand for pet technology and health-oriented products, which reflects younger pet owners' balancing act between wellness and affordability.
  • Emergence of a Two-Speed Market: Industry experts noted a bifurcation in spending patterns, where affluent households continue to purchase premium products while approximately 75% of households shift towards value brands, benefiting private-label producers.
  • Investor Focus: Despite a slowdown in overall deal activity, the pet care sector remains attractive to investors due to its stable demand and lower tariff exposure, with analysts predicting a significant increase in transaction activity in 2026 and 2027, particularly in premium and value segments.
Benzinga
8.5
2025-12-17Benzinga
Cardone Ventures Proposes Complete Acquisition of PetMed Express, Shares Surge
  • PetMed Express Stock Surge: PetMed Express, Inc. shares rose nearly 36% after an unsolicited takeover bid from Cardone Ventures was announced, leading to increased investor interest.

  • Takeover Proposal Details: Cardone Ventures proposed an all-cash offer of $4.25 per share, valuing the company at approximately $89 million, with no financing contingencies indicated.

  • Strategic Appeal of Acquisition: Cardone Ventures highlighted the attractiveness of PetMed's national pharmacy platform and operational capabilities, suggesting that private ownership could enhance performance and profitability.

  • Non-Binding Nature of Offer: The proposal is non-binding, meaning that a definitive agreement may not be reached, and the deal could ultimately not close.

Newsfilter
8.5
2025-12-16Newsfilter
Cardone Ventures Proposes $4.25 Per Share Acquisition of PetMed Express
  • Acquisition Proposal: Cardone Ventures has submitted a proposal to acquire PetMed Express for $4.25 per share in cash, implying an equity value of approximately $89 million, reflecting confidence in its ability to execute the transaction and enhance operational efficiency through privatization.
  • Strategic Importance: Cardone Ventures views PetMeds as a strategically valuable acquisition with strong brand equity and customer relationships, aiming to leverage its expertise in acquisitions and operations to drive significant business growth and unlock long-term shareholder value post-privatization.
  • Leadership Team Advantage: The leadership team at Cardone Ventures, including experienced operators Brandon Dawson and Natalie Dawson, has successfully scaled the firm to $225 million in revenue within five years, showcasing their strong execution capabilities and expertise in value creation.
  • Transaction Terms Overview: The proposal is non-binding and free of financing contingencies, requiring customary due diligence and necessary approvals, indicating Cardone Ventures' optimistic outlook on PetMeds despite the non-binding nature of the offer.

Valuation Metrics

The current forward P/E ratio for Petmed Express Inc (PETS.O) is -31.43, compared to its 5-year average forward P/E of -10.63. For a more detailed relative valuation and DCF analysis to assess Petmed Express Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.63
Current PE
-31.43
Overvalued PE
99.28
Undervalued PE
-120.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.25
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
15.86
Undervalued EV/EBITDA
4.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.01
Current PS
0.35
Overvalued PS
1.70
Undervalued PS
0.31

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what is the best penny stock for tomorrow
Intellectia · 72 candidates
Market Cap: >= 50.00MPrice: $0.10 - $5.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 60One Day Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
LU logo
LU
Lufax Holding Ltd
2.31B
AMTX logo
AMTX
Aemetis Inc
98.64M
BLNK logo
BLNK
Blink Charging Co
117.51M
IOVA logo
IOVA
Iovance Biotherapeutics Inc
996.39M
BBD logo
BBD
Banco Bradesco SA
39.45B
WWR logo
WWR
Westwater Resources Inc
126.25M

Whales Holding PETS

O
Oaktop Capital Management II, L.P.
Holding
PETS
-3.04%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Petmed Express Inc (PETS) stock price today?

The current price of PETS is 2.23 USD — it has decreased -3.46

What is Petmed Express Inc (PETS)'s business?

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

What is the price predicton of PETS Stock?

Wall Street analysts forecast PETS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PETS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Petmed Express Inc (PETS)'s revenue for the last quarter?

Petmed Express Inc revenue for the last quarter amounts to 40.66M USD, decreased -21.75

What is Petmed Express Inc (PETS)'s earnings per share (EPS) for the last quarter?

Petmed Express Inc. EPS for the last quarter amounts to -0.50 USD, increased 1566.67

How many employees does Petmed Express Inc (PETS). have?

Petmed Express Inc (PETS) has 173 emplpoyees as of March 29 2026.

What is Petmed Express Inc (PETS) market cap?

Today PETS has the market capitalization of 47.72M USD.